logo-loader
viewValiRx PLC

ValiRx secures US patent for VAL201 cancer drug

ValiRx had already been granted worldwide rights for the use of VAL201 in prostate cancer, and US officials have now allowed claims for the use of the drug in the prevention and treatment of metastatic cancer, including prostate cancer

us patent and trademark office in virginia
VAL201 is currently in a phase I/II clinical trial

ValiRx Plc (LON:VAL) has been awarded a US patent covering the use of its VAL201 drug in the prevention and treatment of metastatic cancer, including prostate cancer.

VAL201, which is currently in a phase I/II clinical study, already has patent protection in other markets around the world.

READ: ValiRx agrees break fee as it terminates financing agreement

The compound works to prevent tumour growth by specifically inhibiting the proliferation of tumour cells. Its inhibitory effects on lymph node metastases have been demonstrated in the pre-clinical prostate cancer model.

In the ongoing clinical trial, VAL201 has so far shown itself to be well-tolerated, with “signs of activity” in advanced prostate cancer noted through biomarker and imaging techniques.

“With previously granted worldwide rights for the use of VAL201 in prostate cancer, we are very pleased that the US Patent and Trademark Office has allowed claims for the use of VAL201 in the prevention and treatment of metastatic (including prostate) cancer,” said chief executive Satu Vainikka.

“I believe that not only will the allowed claims complement our other intellectual property  and provide the company with a more compelling package to offer when in discussions with big pharma, but I also believe that if we can reduce the symptoms and progression of metastases, as well as targeting the lesion,  through the use of VAL201, we can improve prospects for patients.”

In Wednesday afternoon trading, ValiRxshares were down 7.1% to 0.21p.

--Adds share price--

Quick facts: ValiRx PLC

Price: 0.1275 GBX

AIM:VAL
Market: AIM
Market Cap: £1.7 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ValiRx PLC named herein, including the promotion by the Company of ValiRx PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: Green light for ValiRx to increase dose of VAL201

Top stories from the Proactive Investors UK newsroom. ValirX (LON:VAL) has received a boost for its prostate cancer treatment VAL201 after UK regulators approved a substantial increase in the doses allowed in future clinical trials. The phase I/II trial so far has met all primary and...

on 20/6/19

RNS

Holding(s) in Company

1 week, 2 days ago

Appointment of Joint Broker

1 week, 2 days ago

Holding(s) in Company

1 week, 4 days ago

Half-year Report

on 26/9/19

Company Update

on 24/9/19

2 min read